Searchable abstracts of presentations at key conferences in endocrinology

ea0014p142 | (1) | ECE2007

Dopamine receptor expression and dopamine agonist effectiveness in post-surgical persistent medullary thyroid cancer

Pivonello Rosario , Ferolla Piero , Faggiano Antongiulio , Ferone Diego , Cerasola Enrica , Angeletti Gabriella , Santeusanio Fausto , Minuto Francesco , Lombardi Gaetano , Lamberts Steven WJ , Hofland Leo J , Colao Annamaria

Dopamine receptors was suggested to be expressed in medullary thyroid cancer (MTC). The aim of the current study was to evaluate the expression of D2 dopamine receptor in MTC and the effectiveness of the dopamine agonist cabergoline in patients with MTC. Five paraffin-embedded cases of MTC obtained after thyroidectomy were used to evaluate D2 receptor expression by immunohistochemistry. Fifteen patients (7 males, 8 females, 36–78 years) with post-sur...

ea0026p247 | Pituitary | ECE2011

A multicenter study on acromegalic patients treated with pegvisomant monotherapy or with pegvisomant plus somatostatin analogues: role of exon 3 deleted GH receptor polymorfism

Filopanti Marcello , Olgiati Luca , Lania Andrea , Beck-Peccoz Paolo , De Marinis Laura , Grottoli Silvia , Martini Chiara , Cannavo Salvatore , Bogazzi Fausto , Ferone Diego , Arnaldi Giorgio , Peri Alessandro , Tita Patrizia , Pigliaru Francesca , Angeletti Gabriella , Jaffrain-Rea Marie-Lise , Losa Marco , Spada Anna

Introduction: To date, two pharmacogenetic studies investigated the effect of the common exon 3 deletion of GH receptor (d3-GHR) variant in small series of acromegalic patients treated with Pegvisomant (Peg), suggesting an association of d3-GHR allele with better response to Peg.Aim: To assess the influence of d3-GHR variant in a large cohort of acromegalics with active disease and resistance to somatostatin analogues (SSA) treated with either Peg monoth...